Charles Schwab Investment Management Inc. acquired a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 73,146 shares of the company’s stock, valued at approximately $1,498,000. Charles Schwab Investment Management Inc. owned approximately 0.20% of Rapport Therapeutics as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. ARCH Venture Management LLC acquired a new position in shares of Rapport Therapeutics during the 2nd quarter valued at about $86,730,000. Johnson & Johnson purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at about $58,105,000. Sofinnova Investments Inc. purchased a new stake in Rapport Therapeutics in the 2nd quarter valued at $45,393,000. Perceptive Advisors LLC purchased a new stake in Rapport Therapeutics during the 2nd quarter valued at approximately $17,403,000. Finally, Logos Global Management LP acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter worth $4,859,000.
Rapport Therapeutics Price Performance
NASDAQ:RAPP opened at $18.56 on Tuesday. Rapport Therapeutics has a 1 year low of $16.55 and a 1 year high of $29.74. The business has a fifty day simple moving average of $23.13.
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Read More
- Five stocks we like better than Rapport Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- Top Biotech Stocks: Exploring Innovation Opportunities
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Want to see what other hedge funds are holding RAPP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rapport Therapeutics (NASDAQ:RAPP – Free Report).
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.